Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Peptides for Treatment of Tumor Necrosis Factor alpha Mediated Inflammatory Disease

Posted Sep 27 2012 8:00pm

Description of Invention:
Tumor Necrosis Factor alpha (TNF-alpha) is a multifunctional cytokine that mediates inflammation, immune regulation, and cellular proliferation. This cytokine is converted to its active form by TNF-alpha converting enzyme (TACE). Pathological increases in TNF-alpha activity have been associated with a wide variety of inflammatory diseases, including inflammatory bowel disease, rheumatoid arthritis, and cancer. Inhibiting the conversion of TNF-alpha to its active form by inhibiting TACE represents a potential treatment for these diseases.

The current technology provides peptides, derived from an N-terminal fragment of the TACE protein, that inhibit TACE activity. Also described are methods of using these peptides to lower levels of active TNF-alpha. These peptides could be used as a treatment for TNF-alpha-mediated inflammatory diseases.

Applications:
Treatment of TNF-alpha mediated inflammatory diseases.

Advantages:
Inhibition of TACE activity represents a novel mechanism to treat inflammatory disease.

Development Status:
  • Early-stage
  • In vitro data available


Inventors:
Stewart J Levine (NHLBI)


Patent Status:
HHS, Reference No. E-208-2003/0
US, , Patent No. 7,655,752, Issued 02 Feb 2010


Relevant Publication:
  1. Buckley CA, et al. [ PMID 15749738 ]



For Licensing Information Please Contact:
Tara Kirby Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: tk200h@nih.gov
Phone: 301-435-4426
Fax: 301-402-0220


Ref No: 778

Updated: 09/2012

Post a comment
Write a comment: